The p.Val1740Leu mutation in SCN9A, identified in all affected family members, but not in any unaffected members, suggested that the clinical condition in this family may be regarded as a novel variant of PEPD. This evidence concerns the gene SCN9A and paroxysmal extreme pain disorder.